Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
03/2003
03/20/2003US20030054981 Parenteral formulation of an echinocandin compound, the micelle-forming surfactant, and a nontoxic, aqueous solvent, in given weight ratio of surfactant to echinocandin; treating fungal infections
03/20/2003US20030054979 Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
03/20/2003US20030054532 Reduction in aggregation of enzymes in liquid solutions; obtain sample containing enzymatic polypeptide, incubate with modulator, monitor adjustment in aggregation activity
03/20/2003US20030054063 Tablet press machine
03/20/2003US20030054046 Hydrated dressing containing metal microbiocide
03/20/2003US20030054045 Formulations for therapeutic agents absorbed through mucous membranes
03/20/2003US20030054044 Novel drug delivery technology
03/20/2003US20030054043 Thixotropic oil based vehicle for pharmaceutical compositions
03/20/2003US20030054042 Stabilization of chemical compounds using nanoparticulate formulations
03/20/2003US20030054041 Modified release formulations containing a hypnotic agent
03/20/2003US20030054040 Solid solution of bioactive material in glass; bombardment administering
03/20/2003US20030054039 Edible film formulations containing maltodextrin
03/20/2003US20030054038 Mixture of drug and enteric acid polymer; neutralization
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054036 Mixture of block polymer; solvent and drug
03/20/2003US20030054035 Biodegradation membrane
03/20/2003US20030054034 Water soluble film forming polymer and microbiocide oil
03/20/2003US20030054033 Sustained release; therapy for attention deficit disorders
03/20/2003US20030054032 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
03/20/2003US20030054031 Controlled release oral dosage form
03/20/2003US20030054030 Topical applying mixture of active material and lipid; side effect reduction
03/20/2003US20030054029 Iib/iiia antagonists co-administered with aspirin
03/20/2003US20030054028 Sustained releasing drug in situ
03/20/2003US20030054027 Charged lipids and uses for the same
03/20/2003US20030054026 Athletic patch
03/20/2003US20030054007 Intracellular protein delivery compositions and methods of use
03/20/2003US20030053983 Colloidal metal compositions and methods
03/20/2003US20030053978 Antitumor agents
03/20/2003US20030053973 Topical composition for follicular delivery of an ornithine decarboxylase inhibitor
03/20/2003US20030053965 Oil in water emulsions; sunscreen agents, antiaging agent
03/20/2003US20030053960 Powder formulation
03/20/2003US20030053959 Breathing a dry powder; antidiabetic agent
03/20/2003US20030053958 For treating pulmonary hypertension; sustained release; has no effect on heart rate
03/20/2003US20030053957 Degradation-resistant glucocorticosteroid formulations
03/20/2003US20030053956 Alkylaryl polyether alcohol polymers for treatment and prophylaxis of snoring, sleep apnea, sudden infant death syndrome and for improvement of nasal breathing
03/20/2003US20030053953 Wherein void comprises vapor of volatile liquid (aliphatic hydrocarbons, chlorofluorocarbons, tetraalkyl silanes, and perfluorocarbons); for computed tomography imaging of the gastrointestinal region
03/20/2003US20030053372 Preparation of liquid dispersions
03/20/2003US20030051728 Method and device for delivering a physiologically active compound
03/20/2003DE20216598U1 Wart-removing product comprises an air-impermeable covering
03/20/2003CA2460190A1 Transdermal administration of an enalapril ester
03/20/2003CA2459426A1 Human immunodeficiency virus envelope glycoprotein mutants and uses thereof
03/20/2003CA2459333A1 A pellet implant system and method of administration
03/20/2003CA2459280A1 Device and method to maintain vascularization near implant
03/20/2003CA2459120A1 Human tissue urokinase type plasminogen activator formulation
03/20/2003CA2458547A1 Fluid-to-powder compositions
03/20/2003CA2457895A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
03/20/2003CA2457851A1 Use of hcg and lh in controlled ovarian hyperstimulation
03/20/2003CA2457849A1 Use of hcg in controlled ovarian hyperstimulation
03/20/2003CA2457717A1 Use of compounds in a dry powder inhaler
03/20/2003CA2452194A1 Sustained release pharmaceutical compositions comprising a silicone support material
03/20/2003CA2357511A1 Genital lubricating compositions and uses thereof
03/19/2003EP1293248A1 Novel calixarene based dispersible colloidal system in the form of nanoparticles
03/19/2003EP1293226A1 Disposable personal aromatherapy mask kit
03/19/2003EP1293208A1 Pharmaceutical formulation
03/19/2003EP1293206A1 Water-based liquid preparation
03/19/2003EP1293204A1 Urea-containing gel preparation
03/19/2003EP1293199A1 Plaster
03/19/2003EP1293198A1 Device for transdermal administration for the treatment of urinary tract disorders
03/19/2003EP1293197A1 Process for producing phospholipid-containing drugs
03/19/2003EP1293196A2 Pharmaceutical composition comprising doxazosin
03/19/2003EP1293195A1 Oral pharmaceutical dosage forms with reduced potential for drug abuse, comprising respiratory irritants or bitter substances
03/19/2003EP1293194A1 Physically stable sprayable gel composition
03/19/2003EP1293131A1 Throat care agents
03/19/2003EP1293126A1 Ophthalmic solution and contact lens solution
03/19/2003EP1292639A2 Highly flexible starch-based films
03/19/2003EP1292628A1 Process for the manufacture of hydrogel compositions and hydrogel compositions manufactured thereby
03/19/2003EP1292618A2 Vip-related peptides for the treatment of sexual disorders in women
03/19/2003EP1292612A2 Glycopeptide phosphonate derivatives
03/19/2003EP1292611A2 Glycopeptide carboxy-saccharide derivatives
03/19/2003EP1292605A2 Antisense modulation of inhibitor of dna binding-1 expression
03/19/2003EP1292598A1 Process for drying amoxicillin
03/19/2003EP1292539A1 Micronised barium sulphate
03/19/2003EP1292386A2 Novel microcapsules
03/19/2003EP1292385A1 Method and facility for producing micromembrane capsules
03/19/2003EP1292381A1 Process and device for producing liquid dosage formulations
03/19/2003EP1292359A2 System and method for assessing the performance of a pharmaceutical agent delivery system
03/19/2003EP1292347A1 Drug delivery apparatus
03/19/2003EP1292340A1 Transfection system
03/19/2003EP1292325A1 Matrix protein compositions for dentin regeneration
03/19/2003EP1292315A2 Methods and compositions using sulodexide for the treatment of diabetic nephropathy
03/19/2003EP1292314A2 Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans
03/19/2003EP1292309A1 Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
03/19/2003EP1292303A1 A stable pharmaceutical formulation comprising torsemide modification ii
03/19/2003EP1292298A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
03/19/2003EP1292293A1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
03/19/2003EP1292286A1 Dry-powder pharmaceutical formulation for inhalation comprising alpha4-integrin antagonist
03/19/2003EP1292285A1 Delivery systems for bioactive agents
03/19/2003EP1292284A2 Encapsulation of polynucleotides and drugs into targeted liposomes
03/19/2003EP1292283A1 A medicinal aerosol formulation
03/19/2003EP1292282A2 Improved injectable dispersions of propofol
03/19/2003EP1292281A1 Novel tiotropium-containing inhalation powder
03/19/2003EP1292280A2 Multiple stimulus reversible hydrogels
03/19/2003EP1292279A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
03/19/2003EP1222033A4 Pore structures for reduced pressure aerosolization
03/19/2003EP1151746B1 Microcapsules for sustained release of drugs
03/19/2003EP1146964B1 Milling process for the production of finely milled medicinal substances
03/19/2003EP1140088A4 Controlled/modified release oral methylphenidate formulations
03/19/2003EP1140014B1 Osmotic delivery system having space efficient piston
03/19/2003EP1137671B1 Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions
03/19/2003EP1102579B1 Medicinal aerosol formulations
1 ... 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 ... 2991